UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000040694
Receipt number R000046448
Scientific Title SUrveillance of SARS-CoV-2 Virus Antibody in Health CarE and CloSe-Contact WorkerS
Date of disclosure of the study information 2020/06/09
Last modified on 2020/06/09 08:55:45

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

SUrveillance of SARS-CoV-2 Virus Antibody in Health CarE and CloSe-Contact WorkerS

Acronym

SUCCESS

Scientific Title

SUrveillance of SARS-CoV-2 Virus Antibody in Health CarE and CloSe-Contact WorkerS

Scientific Title:Acronym

SUCCESS

Region

Japan


Condition

Condition

Coronavirus disease-19

Classification by specialty

Infectious disease

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Assessment of COVID 19 antibody positivity in health-care professions and workers

Basic objectives2

Others

Basic objectives -Others

none

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

We examine the distribution of antibody positivity against COVID-19 among health-care professions and workplace workers at high risk of infection, using either the POC test kit or the laboratory test.

Key secondary outcomes

none


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

No need to know


Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Other

Interventions/Control_1

Both COVID-19 antibody POC test kit and the laboratory test are not approved, and therefor this study is intervention research.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)adult more than 20 years-old
2)health-care professions
3)workers who have many opportunities to interact with peoples(sales, face-to-face work sites, and crowded works)

Key exclusion criteria

1)persons under 20
2) persons who did not get consent
3) persons who are judged to be inappropriate for inclusion in the study by the principal investigator / partner and the medical staff involved in the study

Target sample size

1000


Research contact person

Name of lead principal investigator

1st name Masakatsu
Middle name
Last name Nishikawa

Organization

Kinki Health Administration Center (KKC)

Division name

Mie Health Checkup Clinic

Zip code

514-0131

Address

4-1-3 Anotsudai, Tsu, Mie 514-0131, JAPAN

TEL

059-253-7426

Email

nishikawa17635@gmail.com


Public contact

Name of contact person

1st name Masakatsu
Middle name
Last name Nishikawa

Organization

Kinki Health Administration Center (KKC)

Division name

Mie Health Checkup Clinic

Zip code

514-0131

Address

4-1-3 Anotsudai, Tsu, Mie 514-0131, JAPAN

TEL

0592537426

Homepage URL


Email

nishikawa17635@gmail.com


Sponsor or person

Institute

Kinki Health Administration Center,
Mie Health Checkup Clinic

Institute

Department

Personal name



Funding Source

Organization

Kinki Health Administration Center

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Central Research Ethic Committee, Kinki Health Administration Center

Address

10-10 Kinoshita-cho, Ootsu, Shiga 520-0812, JAPAN

Tel

077-525-5418

Email

t_hachio@zai-kkc.or.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 06 Month 09 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2020 Year 05 Month 21 Day

Date of IRB

2020 Year 05 Month 26 Day

Anticipated trial start date

2020 Year 06 Month 10 Day

Last follow-up date

2021 Year 03 Month 31 Day

Date of closure to data entry

2021 Year 05 Month 31 Day

Date trial data considered complete

2021 Year 07 Month 31 Day

Date analysis concluded

2021 Year 09 Month 30 Day


Other

Other related information



Management information

Registered date

2020 Year 06 Month 09 Day

Last modified on

2020 Year 06 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046448


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name